eHealth (EHTH) Q2 2026 Earnings Call Transcript

eHealth reported Q2 2026 revenue of $33.6M, down 45% YoY, and a GAAP net loss of $23.6M (vs. a $17.4M loss in Q2 2025). The company emphasized improving operating cash flow (Q2 operating cash flow -$5M vs. -$41.2M YoY) alongside cost actions targeting >$60M annual variable savings and ~$30M fixed savings, while ending the quarter with ~$101M in cash and marketable securities. Guidance was reiterated for 2026: revenue $405M–$445M and adjusted EBITDA $55M–$75M, with operating cash flow expected to range from -$10M to +$12M. Management also highlighted a new lifetime advisory model and AI-enabled call screening ahead of 2026 AEP, while noting Medicare broker commission policy for plan year 2027 caps at 4.5% (per CMS).

Analysis

This is a deliberate shrink-to-grow reset, not a clean inflection. For the next 1-2 quarters, reported revenue likely stays under pressure because management is pulling back acquisition spend to buy adviser time and retention; that means headline growth is the wrong KPI until AEP data proves the new model can replace volume with higher-value cohorts. The key mechanism is whether ancillary attach and retention can lift cash conversion faster than lower MA starts compress the top line; if not, the business is just harvesting a smaller base.

The second-order winners are carrier balance sheets and larger branded distributors. If Medicare carriers keep prioritizing margin discipline, brokers with weak brand and heavy affiliate dependence should lose share first, while platforms with better direct consumer relationships can monetize fewer but better-quality enrollments. The risk is that this “stability” is fragile: a return of non-commissionable plans or higher terminations in AEP would hit EHTH twice — lower commissionability and lower conversion on the very channels it is trying to protect.

The balance sheet deserves more skepticism than management does. A rising receivables balance alongside falling revenue makes cash flow look better only if carrier payments and reserves behave; any slippage there would show up fast in equity value because the market will not pay up for a refinancing story with declining organic volume. The contrarian bull case is that the market is underestimating the durability of retention and the cash timing benefit of ancillary products, but that needs four quarters of proof, not one quarter of commentary.

Key Decisions for Investors

• Short EHTH on any post-earnings bounce; 1-3 month horizon into the next AEP prep update. Thesis: Q3 should show another step-down in revenue before any proof of the advisory model arrives. Risk/reward improves if the stock re-rates on cash-flow language without a matching top-line inflection.
• If options are liquid, prefer a 3-6 month EHTH put spread rather than outright puts. The catalyst is a negative revenue mix and potential AEP disappointment, while the spread limits theta decay if the stock grinds rather than breaks.
• Pair trade: long a managed-care carrier basket proxy such as UNH/HUM, short EHTH, for 1-3 months. The spread expresses the view that commission discipline and plan rationalization help carriers more than brokers. Falsify if carriers signal broader commission cuts or meaningful plan disruption in 2027.
• Do not buy the stock purely on cash-flow improvement until Q3 retention and ancillary attach data are reported. Missing data to watch: cohort retention, cross-sell durability, and any change in commissionability; if those metrics hold for a full AEP cycle, the bearish case weakens materially.
• Set a hard alert on any revised 2026 revenue or operating cash flow guidance. A guidance cut or evidence that receivables quality is slipping would be the cleanest trigger to add to the short.